ATLAS Neo Study
A Phase 3, Single-arm, Multicenter, Multinational, Open-label, One-way Crossover Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged ≥ 12 Years With Severe Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX
SEX AT BIRTH: Male
HEALTHY PARTICIPANTS: No
CONDITION: Severe Congenital Hemophilia A or B
Learn More About This Research Study
For more information, please contact study coordinator, Megan Schneider at 216-844-7445 or complete the form below.
Study Purpose
The purpose of this research study is to determine if the frequency of treated bleeding episodes is reduced in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX who have switched from their prior standard of care treatment to fitusiran treatment. The total study duration will be up to approximately 50 months (200 weeks, 1 study month is equivalent to 4 weeks).
Who Can Participate
Males 12 years or older who are diagnosed with severe congenital hemophilia A or B may be eligible for this study.
- STUDYID#20230469
- NCT05662319